Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phase II Clinical Trial of Trametinib and Low-Dose Dabrafenib in Advanced, Previously Treated BRAFV600/NRASQ61 Wild-Type Melanoma (TraMel-WT)

1 Feb 2024

Abstract excerpt

PURPOSE: wild-type melanoma who progress after immune checkpoint inhibitors (ICIs) have a poor prognosis. MEK inhibition has shown activity in this patient population but is associated with treatment-limiting skin toxicity. Combining a BRAF inhibitor with a MEK inhibitor is associated with less skin toxicity. METHODS: wild-type, ICI-refractory melanoma. In case of treatment-limiting skin toxicity, low-dose...

Topics

Join the communities discussing this publication.

Cutaneous Melanoma Detection and Management
Melanoma and MAPK Pathways
Ocular Oncology and Treatments

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 39374099
DOI: 10.1200/po.23.00493

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase II Clinical Trial of Trametinib and Low-Dose Dabrafenib in Advanced, Previously Treated BRAFV600/NRASQ61 Wild-Type Melanoma (TraMel-WT)PMID 39374099Read ↗

Combination dabrafenib and trametinib in the management of advanced melanoma with BRAFV600 mutations.Semantic proximity Read ↗

Dabrafenib plus Trametinib: a Review in Advanced Melanoma with a BRAF (V600) Mutation.Semantic proximity Read ↗

Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial.Semantic proximity Read ↗

Trametinib in the treatment of melanoma.Semantic proximity Read ↗

Future of combination therapy with dabrafenib and trametinib in metastatic melanoma.Semantic proximity Read ↗

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.Semantic proximity Read ↗

Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.Semantic proximity Read ↗

Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor.Semantic proximity Read ↗

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.Semantic proximity Read ↗

Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.Semantic proximity Read ↗

Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.Semantic proximity Read ↗

Improved overall survival in melanoma with combined dabrafenib and trametinib.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.